Almost every question about what low-dose naltrexone costs has the same answer hiding inside it: there is no approved product at this dose, so somebody has to make it for you. Naltrexone is licensed in the United States as a 50 mg film-coated tablet for opioid and alcohol use disorder.[1] LDN is the same molecule at roughly 1.5–4.5 mg — a strength no manufacturer produces, for indications no regulator has evaluated. That means it is both off-label and sub-strength, and the second of those is the expensive one. Off-label prescribing of an existing product costs nothing extra; prescribing a strength that does not exist requires a compounding pharmacy to prepare it. Everything below follows from that.
~$1.16
National average acquisition cost of one generic 50 mg naltrexone tablet
CMS NADAC, effective 22 July 2026
None
FDA-approved oral naltrexone products at an LDN strength
approved labeling: 50 mg tablet only
Usually $0
What insurance contributes to a compounded, off-label prescription
cash-pay in practice
Why LDN has no price list
Most drugs have a price you can look up because they are manufactured products with a national drug code, a wholesaler, and a pharmacy benefit that adjudicates them. A compounded preparation has none of that. A compounding pharmacy takes bulk drug substance or a manufactured tablet and prepares an individual patient’s capsules or oral liquid to a prescriber’s specification, and it prices that work itself. Two pharmacies in the same city can quote materially different numbers for an identical prescription, and neither is wrong — they are pricing labour, batch size and overhead, not a listed product.
The regulatory half of that is worth being blunt about, because it is also what makes the prescription uninsurable. The FDA’s position on compounded medicines is that they are not FDA-approved, and that the agency “does not verify the safety, effectiveness or quality of compounded drugs before they are marketed.”[2] Compounding is legal, long-established and genuinely necessary — it is how children get liquid versions of adult tablets, and how people with allergies get a formulation without the offending excipient. But a compounded capsule is not a generic, and the review that stands behind an approved product has not happened here. You are buying a preparation, and the pharmacy’s own quality practices are the assurance. The same regulatory logic we set out for compounded versus branded medicines applies directly: ask what testing the pharmacy does, and get the answer before you pay.
The one number that is actually sourceable: the drug is nearly free
Here is the figure we can stand behind, because it comes from a public federal pricing survey rather than a marketing page. The Centers for Medicare & Medicaid Services publishes the National Average Drug Acquisition Cost (NADAC), a survey of what retail community pharmacies actually pay to acquire a drug. In the file effective 22 July 2026, generic naltrexone 50 mg tablets carried a NADAC of about $1.16 per tablet.[3]
Read that carefully, because it is not your price. NADAC is an acquisition cost — what the pharmacy pays the wholesaler, before dispensing fees, before margin, and for the 50 mg tablet rather than a compounded low dose. What it establishes is the thing that reframes the whole question: the active ingredient in a month of LDN is worth a few dollars at most. A 4.5 mg dose is roughly a ninth of a tablet. Whatever your monthly bill turns out to be, essentially none of it is naltrexone. It is the compounding, the prescriber, and the fact that the product you need does not exist.
What you are actually paying for
Three line items, and only the middle one is about the medicine.
The prescriber. Someone has to write it, off-label, for an indication with no approval. Many primary-care clinicians will not, which is why a large share of LDN is prescribed through telehealth services that market specifically to people seeking it. That visit is a real cost, and it often recurs — a follow-up to titrate, an annual review to keep the prescription active. It is also, in the honest accounting, the most variable item: a clinician you already see who is willing to write it costs you a copay; a specialist telehealth service costs whatever it charges. Whether a prescriber will write it at all is not a niche problem, either. When Norwegian LDN prescribing surged after a 2013 television documentary, 20% of all doctors in the country — and 71% of general practitioners — wrote at least one LDN prescription, dispensing to 0.3% of the population at a median daily dose of 3.7 mg.[6] Willingness to prescribe off-label varies enormously by country, by system and by clinician.
The compounded prescription. This is the recurring line. It is priced per fill by the pharmacy, and it is the number you should be asking two pharmacies to quote. We are deliberately not publishing a national figure, because there isn’t one to publish: compounded preparations are cash-priced by each pharmacy, no federal survey tracks them the way NADAC tracks manufactured generics, and any single dollar range you read online — including the low-tens-of-dollars-a-month figure that circulates in patient communities — is one pharmacy’s quote generalised. Ask for the price per 30 days and per 90 days, and ask whether a titration pack of multiple strengths is billed separately.
Insurance — usually nothing. Two separate barriers stack here, and either one is enough. The use is off-label, so there is no covered diagnosis to adjudicate against; and the product is compounded, so it is not an FDA-approved drug in the plan’s formulary sense.[2] The practical result is that LDN is a cash-pay prescription for almost everyone. The irony is sharp: the 50 mg tablet, at about a dollar a tablet, is a covered generic for its approved indications[1][3] — it is the low dose, the cheap one, that falls outside coverage.
What moves the price up or down
| How it is prepared | What drives the cost | The trade-off |
|---|---|---|
| Compounded capsules (most common) | Pharmacy labour and batch size; the number of capsules dispensed; whether a titration schedule requires two or three separate strengths | The standard route, and the one with a defined per-capsule dose — but a multi-strength titration can mean paying for several prescriptions at once |
| Compounded oral liquid or suspension | Same labour, plus a shorter beyond-use date, which can force more frequent fills | Lets you dose in fractions of a millilitre, which suits slow titration and very low starting doses — at the cost of measuring accurately every night and refilling sooner |
| 30-day versus 90-day fill | Per-fill compounding labour is largely fixed, so a longer fill usually lowers the cost per day | Cheaper per month, but you have committed to a supply before you know whether it does anything for you |
| Dividing or dissolving the 50 mg tablet | The tablet itself: a generic at roughly $1.16 acquisition cost each | By far the cheapest, and the least accurate — the approved tablet is film-coated and made in one strength only, with no assurance of dose uniformity in a fraction of it |
The 50 mg tablet workaround, described honestly
Because the tablet is cheap and the compounding is not, people divide or dissolve the approved 50 mg tablet instead. This is a real and widely discussed practice — a dermatology research letter has been published describing dilution of the tablet in orange juice as an inexpensive alternative to compounding.[5] We are describing it because a cost page that pretended it did not exist would be useless. We are not giving a method, and we are not suggesting it.
The reason to be cautious is measurable rather than theoretical. The approved product is a film-coated tablet manufactured in a single 50 mg strength — it is not scored for division and was never designed to be split.[1] And splitting tablets is less accurate than it looks even in the easy case. In a study that split ten tablets each of sixteen commonly used medications and assayed the halves, 15.0% of the resulting half-tablets fell outside a proxy USP content-uniformity specification, with the variation traced largely to powder and fragment loss during splitting; several drugs failed the test outright.[4] That is for cutting a tablet in half, with a knife, under study conditions. An LDN dose is roughly a ninth to a thirtieth of a 50 mg tablet, which is a far harder division. Dissolving a tablet in a fixed volume of liquid and measuring a fraction avoids the crumbling problem but introduces others: naltrexone is the minority of the tablet by mass, the excipients are not all soluble, and no beyond-use date or stability data attaches to a solution made on a kitchen counter.
The honest framing is a trade-off, not a hack. You are exchanging a compounding fee for an unknown dose, and the unknown runs in both directions — you may be taking substantially more or less than you think, night to night. If dose precision matters to you, it is what the compounding fee buys.
HSA and FSA accounts
This is the one place where the tax code is more generous than the insurer. The IRS treats amounts paid for prescribed medicines — drugs that require a prescription for their use by an individual — as medical expenses, and that definition is the one health savings accounts and flexible spending accounts work from.[9] LDN is prescription-only, which is exactly the category that language describes. In practice, plan administrators make their own substantiation decisions and some balk at compounded items, so keep the pharmacy receipt showing the prescription, and check with your administrator rather than assuming. The prescriber visit is separately a medical expense on the same logic. It is worth a few minutes: for a cash-pay prescription, paying with pre-tax dollars is the only discount available.
Cheap is not the same as effective
A cost page is where a soft sell would fit most naturally, so we will be explicit instead. Low cost is not evidence of benefit. LDN is genuinely inexpensive relative to almost anything else in chronic pain or autoimmune disease, and its adverse-event profile in trials is close to placebo. Neither of those facts is an efficacy result.
The evidence, which we grade in full in our low-dose naltrexone evidence review, points the other way. In fibromyalgia — the best-studied indication — small crossover pilots were encouraging, and then the larger, independently funded parallel-group trial in 99 women found a between-group pain difference of 0.34 points on an 11-point scale (95% CI −0.95 to 0.27, p = 0.27). That is not a small positive result; it is a null one.[7] In Crohn’s disease, Cochrane pooled the entire randomised literature — two trials, 46 patients — and concluded there is insufficient evidence to allow any firm conclusionsabout the efficacy and safety of LDN.[8] In long COVID and ME/CFS there is no randomised trial to discuss at all.
That does not make a trial of LDN irrational for someone with refractory centralised pain who has already worked through the treatments that do have evidence behind them. It does mean the budgeting question is the same one that governs off-label rapamycin: you are paying a modest but real recurring cost for an unproven outcome. Price it like a bet with a defined stopping rule — eight to twelve weeks against a symptom score you wrote down beforehand — rather than like a bargain you keep renewing because it is only a few dollars.
The honest bottom line
Low-dose naltrexone is cheap for a specific and slightly absurd reason: the molecule is a decades-old generic that costs about a dollar a tablet at acquisition,[3] and expensive for an equally specific one: no approved product exists at the dose people want, so a pharmacy has to make it, no insurer will pay for it, and a prescriber has to be found who will write it off-label.[1][2] Your bill is the prescriber plus the compounding, and both are set locally — which is why the only responsible advice on price is to get two quotes rather than trust a number, ours included. The tablet-splitting shortcut is real, and it trades a compounding fee for a dose you cannot verify.[4][5] And the number at the bottom of the invoice says nothing at all about whether it works: the best fibromyalgia trial was null,[7] and Cochrane called the Crohn’s evidence insufficient.[8] Buy it, if you buy it, knowing exactly which of those two things you are paying for.
This article is cost and access research, not medical advice, and nothing here is a recommendation to start low-dose naltrexone or a recommendation of any particular pharmacy or telehealth service. LDN is prescription-only and is dispensed only as a compounded preparation; compounded medicines are not FDA-approved and are not reviewed for safety, effectiveness or quality before they are dispensed, and naltrexone has no FDA approval at low dose for fibromyalgia, Crohn’s disease, multiple sclerosis, long COVID, ME/CFS or any other indication. Naltrexone blocks the effect of opioid analgesics at any dose and will precipitate withdrawal in anyone physically dependent on opioids, tramadol included: tell every clinician, dentist, surgeon and emergency provider that you take it, and plan around elective surgery with your prescriber. All prices described here vary by pharmacy, plan and region and change over time — obtain your own quotes, and discuss existing liver disease, current medications and any planned procedure with a licensed clinician before starting anything.